Following promising ASCO readout for AMG 510, Amgen looks to identify more KRAS-mutant patients

After making a strong showing at ASCO with data for its KRAS inhibitor in non-small cell lung cancer patients, Amgen will now look to expand the program's options for finding trial-eligible patients.

Amgen Inc. (NASDAQ:AMGN) reported updated Phase I

Read the full 389 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE